LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2
Zhenggang Ren, Jia Fan, Jian Xu, Yuxian Bai, Anjian Xu, Shundong Cang, Chengyou Du, B. Liu, Q. Li, Yi Lu, Y. Chen, Guoliang Shao, Y B Guo, Zewen Chen, Yue Yang, M. Chen, Y. Wang, Hui Zhou
Topics & Concepts
MedicineSorafenibBevacizumabHepatocellular carcinomaInternal medicineGastroenterologyPhases of clinical researchOncologyBiosimilarSurgeryToxicityChemotherapyColorectal Cancer Treatments and StudiesBiosimilars and Bioanalytical MethodsCancer Research and Treatments